Cargando…

Deep learning magnetic resonance imaging predicts platinum sensitivity in patients with epithelial ovarian cancer

OBJECTIVE: The aim of the study is to develop and validate a deep learning model to predict the platinum sensitivity of patients with epithelial ovarian cancer (EOC) based on contrast-enhanced magnetic resonance imaging (MRI). METHODS: In this retrospective study, 93 patients with EOC who received p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lei, Ruilin, Yu, Yunfang, Li, Qingjian, Yao, Qinyue, Wang, Jin, Gao, Ming, Wu, Zhuo, Ren, Wei, Tan, Yujie, Zhang, Bingzhong, Chen, Liliang, Lin, Zhongqiu, Yao, Herui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727155/ https://www.ncbi.nlm.nih.gov/pubmed/36505880 http://dx.doi.org/10.3389/fonc.2022.895177

Ejemplares similares

A Noninvasive Tool Based on Magnetic Resonance Imaging Radiomics for the Preoperative Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
por: Li, Chenchen, et al.
Publicado: (2022)

Identification of a tumor immune-inflammation signature predicting prognosis and immune status in breast cancer
por: Liu, Yajing, et al.
Publicado: (2023)

Construction and Validation of a Platinum Sensitivity Predictive Model With Multiple Genomic Variations for Epithelial Ovarian Cancer
por: Zheng, Hong, et al.
Publicado: (2021)

Platinum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment
por: Chien, Jeremy, et al.
Publicado: (2013)

Complex molecular profile of DNA repair genes in epithelial ovarian carcinoma patients with different sensitivity to platinum-based therapy
por: Seborova, Karolina, et al.
Publicado: (2022)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
por: Chen, Qian, et al.
Publicado: (2022)

Pembrolizumab in FIGO IVB Verrucous Carcinoma of the Vulva: A Case Report
por: Wang, Yuhan, et al.
Publicado: (2021)

Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon
por: Abdallah, Reem, et al.
Publicado: (2023)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Magnetic resonance imaging radiomics to differentiate ovarian sex cord-stromal tumors and primary epithelial ovarian cancers
por: Cheng, Meiying, et al.
Publicado: (2023)

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

Modeling Platinum Sensitive and Resistant High-Grade Serous Ovarian Cancer: Development and Applications of Experimental Systems
por: Cunnea, Paula, et al.
Publicado: (2014)

Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence
por: Nakanishi, Kazuho, et al.
Publicado: (2021)

Overcoming the challenges of drug development in platinum-resistant ovarian cancer
por: Eskander, Ramez N., et al.
Publicado: (2023)

RYBP Inhibits Progression and Metastasis of Lung Cancer by Suppressing EGFR Signaling and Epithelial-Mesenchymal Transition()()
por: Dinglin, Xiaoxiao, et al.
Publicado: (2017)

Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum-Sensitive, Platinum-Resistant, and Platinum-Refractory Epithelial Ovarian Cancer
por: Cantón-Romero, Juan Carlos, et al.
Publicado: (2017)

High Expression of PARP1 in Tumor and Stroma Cells Predicts Different Prognosis and Platinum Resistance in Patients With Advanced Epithelial Ovarian Cancer
por: Zuo, Wei-Wei, et al.
Publicado: (2022)

Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer
por: Zuo, Wei-Wei, et al.
Publicado: (2023)

NUF2 overexpression contributes to epithelial ovarian cancer progression via ERBB3-mediated PI3K-AKT and MAPK signaling axes
por: Leng, Ruobing, et al.
Publicado: (2022)

Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Xu, Yangchun, et al.
Publicado: (2021)

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
por: Matanes, Emad, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Wang, Hongmei, et al.
Publicado: (2021)

Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer
por: Bhatt, Aditi, et al.
Publicado: (2022)

Metabolic reprogramming of three major nutrients in platinum-resistant ovarian cancer
por: Yan, Jinbowen, et al.
Publicado: (2023)

Magnetic resonance imaging radiomics signatures for predicting endocrine resistance in hormone receptor-positive non-metastatic breast cancer
por: Yang, Yaping, et al.
Publicado: (2021)

Overcoming therapeutic resistance to platinum-based drugs by targeting Epithelial–Mesenchymal transition
por: Duan, Xirui, et al.
Publicado: (2022)

A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum‐Sensitive Ovarian Cancer
por: Pignata, Sandro, et al.
Publicado: (2021)

YKL-40 in the diagnosis, prediction of prognosis, and platinum sensitivity in serous epithelial ovarian cancer
por: Kahramanoğlu, İlker, et al.
Publicado: (2018)

FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers
por: Mesquita, Katia A., et al.
Publicado: (2021)

RAD50 deficiency is a predictor of platinum sensitivity in sporadic epithelial ovarian cancers
por: Alblihy, Adel, et al.
Publicado: (2020)

Inhibition of Notch Signaling in Combination with Paclitaxel Reduces Platinum-Resistant Ovarian Tumor Growth
por: Groeneweg, Jolijn W., et al.
Publicado: (2014)

Biomarking and Induction of Apoptosis in Ovarian Cancer Using Bifunctional Polyethyleneimine-Caged Platinum Nanoclusters
por: Zhang, Mengjun, et al.
Publicado: (2022)

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer
por: Howard, David, et al.
Publicado: (2022)

Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
por: Pan, Zhongmian, et al.
Publicado: (2023)

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
por: Buderath, Paul, et al.
Publicado: (2019)

Fusobacterium and Colorectal Cancer
por: Zhou, Ziwei, et al.
Publicado: (2018)

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer
por: Ganapathi, Ram N., et al.
Publicado: (2020)

Predictive Value of HE4 in Platinum-Based Chemotherapy for Ovarian Cancer: A Systematic Review
por: Han, Yue, et al.
Publicado: (2021)

Corrigendum: Biomarking and induction of apoptosis in ovarian cancer using bifunctional polyethyleneimine-caged platinum nanoclusters
por: Zhang, Mengjun, et al.
Publicado: (2022)

Characterization of global research trends and prospects on platinum-resistant ovarian cancer: a bibliometric analysis
por: Duan, Yuanqiong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7gc8ht8k2l6u0kced4uo2lh00l